VIATREXX ANNOUNCES LAUNCH OF INJECTABLE PRODUCTS

Products and Services

(Newark, DE – June 1, 2019) Viatrexx has concluded the steps required to start producing and manufacturing its’ line of sterile injectable products and will begin launching June 1st.

Since the sterile injectables are manufactured, they can be acquired as Rx office stock. They are available as 10 mL multi-dose in packs of one, three, six or twelve vials.

“We are excited to expand our portfolio and take control of manufacturing OTC and sterile injectable products, as well as the listing with the FDA, ” said Stephen Emond, President of Viatrexx.

The Viatrexx line has 89 OTC products of which 42 will be available as sterile injectables. Altogether, Viatrexx will offer 131 products. All the products are going through FDA updating and listing.

The first injectables will be ready for the market in early June, with the entire scope available by late September. The injectables are for the U.S and International market.

During this same period, Viatrexx is producing injectable nutriceuticals, such as NAD+.

Injection training courses for pain/sports medicine, aesthetics, Detox, immune, neural and endocrine are being scheduled throughout the US starting this summer, through Thanksgiving.

For more details, please contact us at the numbers or emails listed below

HO: Info@viatrexx.com, Tel 1-888-743-6652

Mia   mia@viatrexx.com  Tel 203-524-2422

ABOUT VIATREXX: ABOUT VIATREXX Viatrexx is a wellness company and manufacturer dedicated to developing and manufacturing integrative oral, topical and injectable formulas which specialize in addressing key pillars (drainage/detox, repair/regeneration, metabolism/oxygenation and emotional/traumatic scars) which may be linked to underlining causes and regeneration. The products and proprietary manufacturing methods mimic the body’s natural healthy biochemical processes and balance, thereby providing remedies which may have a profound impact. Viatrexx is headquartered in Canada and the United States. These statements have not been evaluated by the Government Authorities. These products are not intended to diagnose, treat, cure or prevent any disease.

Advertisement

Current Issue

Table of Contents

Advertisement

Trending Articles

PERQUE LLC introduces PERQUE DigestivAide™ Herbal Bitters.

ASHBURN, VA – PERQUE LLC announces the launch of PERQUE DigestivAide Herbal Bitters, a novel combination of angelica, burdock, dandelion, fennel, ginger, and yellow dock bitters to be taken before meals to stimulate appetite and promote healthy digestion. The...

Custom Publishing

Quantum Energy Effects on Cell Recovery Rates

Quantum Energy Effects on Cell Recovery Rates

Author: Robert Sheaff, PhD, and Ian Mitchell Abstract This study investigated whether quantum field exposure generated by Leela Quantum Bloc Technology influences cell recovery rates in human cell lines. A series of double-blind experiments were conducted using Human...

Quantum Fields and Frequency Medicine

RAZI BERRY Quantum Fields and Frequency Medicine A Conversation with Philipp Samor von Holtzendorff Fehling on Remote Quantum Technology and Human Performance Interest in frequency medicine and subtle energy technologies continues to grow...

Featured News

Allergy Research News Release

Allergy Research News Release

RAZI BERRY Allergy Research Group Announces Peer-Reviewed Publication Advancing Thyroid and Endocrine Integration Science Collaborative research led by ARG’s Medical Affairs and Scientific Advisory Board reinforces the company’s commitment to thyroid category...